First Time Loading...

Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 23.85 USD 0.38% Market Closed
Updated: Apr 20, 2024

Intrinsic Value

Alkermes Plc is a global biopharmaceutical company. [ Read More ]

The intrinsic value of one ALKS stock under the Base Case scenario is 31.77 USD. Compared to the current market price of 23.85 USD, Alkermes Plc is Undervalued by 25%.

Key Points:
ALKS Intrinsic Value
Base Case
31.77 USD
Undervaluation 25%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Alkermes Plc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ALKS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Alkermes Plc

Provide an overview of the primary business activities
of Alkermes Plc.

What unique competitive advantages
does Alkermes Plc hold over its rivals?

What risks and challenges
does Alkermes Plc face in the near future?

Has there been any significant insider trading activity
in Alkermes Plc recently?

Summarize the latest earnings call
of Alkermes Plc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Alkermes Plc.

Provide P/S
for Alkermes Plc.

Provide P/E
for Alkermes Plc.

Provide P/OCF
for Alkermes Plc.

Provide P/FCFE
for Alkermes Plc.

Provide P/B
for Alkermes Plc.

Provide EV/S
for Alkermes Plc.

Provide EV/GP
for Alkermes Plc.

Provide EV/EBITDA
for Alkermes Plc.

Provide EV/EBIT
for Alkermes Plc.

Provide EV/OCF
for Alkermes Plc.

Provide EV/FCFF
for Alkermes Plc.

Provide EV/IC
for Alkermes Plc.

Show me price targets
for Alkermes Plc made by professional analysts.

What are the Revenue projections
for Alkermes Plc?

How accurate were the past Revenue estimates
for Alkermes Plc?

What are the Net Income projections
for Alkermes Plc?

How accurate were the past Net Income estimates
for Alkermes Plc?

What are the EPS projections
for Alkermes Plc?

How accurate were the past EPS estimates
for Alkermes Plc?

What are the EBIT projections
for Alkermes Plc?

How accurate were the past EBIT estimates
for Alkermes Plc?

Compare the revenue forecasts
for Alkermes Plc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Alkermes Plc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Alkermes Plc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Alkermes Plc compared to its peers.

Compare the P/E ratios
of Alkermes Plc against its peers.

Discuss the investment returns and shareholder value creation
comparing Alkermes Plc with its peers.

Analyze the financial leverage
of Alkermes Plc compared to its main competitors.

Show all profitability ratios
for Alkermes Plc.

Provide ROE
for Alkermes Plc.

Provide ROA
for Alkermes Plc.

Provide ROIC
for Alkermes Plc.

Provide ROCE
for Alkermes Plc.

Provide Gross Margin
for Alkermes Plc.

Provide Operating Margin
for Alkermes Plc.

Provide Net Margin
for Alkermes Plc.

Provide FCF Margin
for Alkermes Plc.

Show all solvency ratios
for Alkermes Plc.

Provide D/E Ratio
for Alkermes Plc.

Provide D/A Ratio
for Alkermes Plc.

Provide Interest Coverage Ratio
for Alkermes Plc.

Provide Altman Z-Score Ratio
for Alkermes Plc.

Provide Quick Ratio
for Alkermes Plc.

Provide Current Ratio
for Alkermes Plc.

Provide Cash Ratio
for Alkermes Plc.

What is the historical Revenue growth
over the last 5 years for Alkermes Plc?

What is the historical Net Income growth
over the last 5 years for Alkermes Plc?

What is the current Free Cash Flow
of Alkermes Plc?

Financials

Balance Sheet Decomposition
Alkermes Plc

Current Assets 1.5B
Cash & Short-Term Investments 1.1B
Receivables 333.2m
Other Current Assets 22.9m
Non-Current Assets 650.7m
Long-Term Investments 39.9m
PP&E 318.4m
Intangibles 85m
Other Non-Current Assets 207.4m
Current Liabilities 520.2m
Accounts Payable 65.6m
Accrued Liabilities 444.3m
Other Current Liabilities 10.3m
Non-Current Liabilities 413.3m
Long-Term Debt 287.7m
Other Non-Current Liabilities 125.6m
Efficiency

Earnings Waterfall
Alkermes Plc

Revenue
1.7B USD
Cost of Revenue
-253m USD
Gross Profit
1.4B USD
Operating Expenses
-990.2m USD
Operating Income
420.1m USD
Other Expenses
-64.4m USD
Net Income
355.8m USD

Free Cash Flow Analysis
Alkermes Plc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ALKS Profitability Score
Profitability Due Diligence

Alkermes Plc's profitability score is 56/100. The higher the profitability score, the more profitable the company is.

56/100
Profitability
Score

Alkermes Plc's profitability score is 56/100. The higher the profitability score, the more profitable the company is.

ALKS Solvency Score
Solvency Due Diligence

Alkermes Plc's solvency score is 83/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Negative Net Debt
Low D/E
Short-Term Solvency
83/100
Solvency
Score

Alkermes Plc's solvency score is 83/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ALKS Price Targets Summary
Alkermes Plc

Wall Street analysts forecast ALKS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALKS is 36.44 USD with a low forecast of 23.23 USD and a high forecast of 52.5 USD.

Lowest
Price Target
23.23 USD
3% Downside
Average
Price Target
36.44 USD
53% Upside
Highest
Price Target
52.5 USD
120% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ALKS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ALKS Price
Alkermes Plc

1M 1M
-14%
6M 6M
-12%
1Y 1Y
-18%
3Y 3Y
+18%
5Y 5Y
-29%
10Y 10Y
-48%
Annual Price Range
23.85
52w Low
23.37
52w High
33.63
Price Metrics
Average Annual Return -2.99%
Standard Deviation of Annual Returns 27.21%
Max Drawdown -62%
Shares Statistics
Market Capitalization 4B USD
Shares Outstanding 170 138 000
Percentage of Shares Shorted 9.79%

ALKS Return Decomposition
Main factors of price return

What is price return decomposition?

ALKS News

Other Videos

Company Profile

Alkermes Plc Logo
Alkermes Plc

Country

Ireland

Industry

Biotechnology

Market Cap

4B USD

Dividend Yield

0%

Description

Alkermes Plc is a global biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 2,211 full-time employees. The firm is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The company has a portfolio of commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. The firm's products include ALKERMES, ARISTADA, ARISTADA INITIO, LinkeRx, LYBALVI, NanoCrystal and VIVITROL. Its other trademark includes INVEGA SUSTENNA, INVEGA TRINZA, TREVICTA, XEPLION, and RISPERDAL CONSTA, KEYTRUDA and VUMERITY. The firm's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Contact

DUBLIN
DUBLIN
Connaught HSE, 1 Burlington Road
+35317728000.0
http://www.alkermes.com/

IPO

1991-07-16

Employees

2 211

Officers

Chairman & CEO
Mr. Richard F. Pops
Interim Principal Financial Officer, Executive VP & COO
Mr. Blair C. Jackson
Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary
Mr. David Joseph Gaffin
Senior VP & CFO (Leave of Absence)
Mr. Iain Michael Brown
Executive VP of Research & Development and Chief Medical Officer
Dr. Craig C. Hopkinson M.D.
Founder
Dr. Floyd E. Bloom M.D.
Show More
Interim Principal Accounting Officer & VP of Finance
Mr. Samuel J. Parisi
Chief Information Officer & Senior VP of IT
Mr. Thomas Harvey
Senior Vice President of Corporate Affairs & Investor Relations
Ms. Sandra Coombs
Senior VP of Corporate Development & Chief Risk Officer
Mr. Michael J. Landine
Show Less

See Also

Discover More
What is the Intrinsic Value of one ALKS stock?

The intrinsic value of one ALKS stock under the Base Case scenario is 31.77 USD.

Is ALKS stock undervalued or overvalued?

Compared to the current market price of 23.85 USD, Alkermes Plc is Undervalued by 25%.